Results 231 to 240 of about 157,199 (404)
EI‐HMP enhances urine output and reduces ICU stay in kidney transplant patients, particularly in ECD grafts, but does not significantly impact long‐term survival or dialysis avoidance. These short‐term benefits suggest EI‐HMP may improve early recovery, although its long‐term efficacy requires further investigation through randomized controlled trials.
Franco Ruberto+12 more
wiley +1 more source
A comparative analysis of drug-induced kidney injury adverse reactions between cyclosporine and tacrolimus based on the FAERS database. [PDF]
Xu M, Xu S, Yi X.
europepmc +1 more source
This multicentre retrospective study from 30 centers worldwide found that upadacitinib was an effective and safe induction therapy for refractory paediatric Crohn's disease. Efficacy should be weighed against the potential risks of adverse events. ABSTRACT Background There are scarce data available on upadacitinib in children with Crohn's disease (CD).
Shlomi Cohen+34 more
wiley +1 more source
Tacrolimus can resolve cyclosporin-induced gingival hyperplasia [PDF]
Prakash Harikrishnan
openalex +1 more source
How to Choose Treatment Regimens for Idiopathic Membranous Nephropathy Patients with PLA2R-Negative: A Single-Center Retrospective Cohort Study. [PDF]
Zhou Z, Zou Y, Ke B, Shen W.
europepmc +1 more source
Current methods of dose determination have contributed to suboptimal and inequitable health outcomes in underrepresented patient populations. The persistent demand to individualise patient treatment, alongside increasing technological feasibility, is leading to a growing adoption of model‐informed precision dosing (MIPD) at point of care.
Monika Berezowska+9 more
wiley +1 more source
Prolongation of canine renal allograft survival by combining tacrolimus with antimetabolic agents [PDF]
A. Urakami+11 more
core +1 more source